Formulations containing thymoquinone for urinary health

Abstract

A novel dietary supplement or therapeutic composition is provided that serves to treat lower urinary tract disorders or to support normal urinary tract function in animals. The supplement comprises a thymoquinone formulation and at least one member of the group consisting of cranberry fruit, cranberry extract, cranberry juice and a pharmaceutical grade methionine.

1. A method of treating inflammation associated with idiopathic cystitis in animals which comprises administering to an animal suffering signs or symptoms of idiopathic cystitis a composition comprising effective amounts of a thymoquinine-enriched oil extract fraction from the ground seeds of  Nigella sativa  and at least one component selected from the group consisting of cranberry fruit, cranberry extract, cranberry juice, and methionine, whereby the oil extract fraction is obtained by:
 (a) extracting the ground  Nigella sativa  seeds with supercritical carbon dioxide at 120-130 bar at 40° C. for 6 hours to obtain a fraction and collecting the fraction; 
 (b) extracting the ground  Nigella sativa  seeds with supercritical carbon dioxide at 160-190 bar at 60° C. for 2 hours to obtain a fraction and collecting the fraction; or 
 (c) extracting the ground  Nigella sativa  seeds with supercritical carbon dioxide at 200 bar at 50° C. for 10 hours to obtain a fraction and collecting the fraction; and continuing administration until said signs or symptoms are reduced or eliminated. 
 
     
     
       2. The method of  claim 1  wherein the animal is a mammal selected from the group consisting of humans, nonhuman primates, dogs, cats, horses or cattle. 
     
     
       3. The method of  claim 1  wherein the administration is oral. 
     
     
       4. The method of  claim 1 , wherein the administration is by injection.